Laboratory for Bioanalysis and Onco-Pharmaceutics, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.
Department of Breast Surgical Oncology, Tokyo Rosai Hospital, Tokyo, Japan.
Cancer Biomark. 2024;41(2):145-154. doi: 10.3233/CBM-240034.
Endocan was reported to affect breast cancer patients negatively and was able to be detected from patients' blood.
This study aimed to investigate if the measurement of blood endocan in breast cancer patients with high ESM1 expression could be an effective tool to detect postoperative recurrence compared with existing tumor markers.
Blood was collected before and after the tumor resection from the mouse models of breast cancer, and endocan levels were measured while visualizing metastatic recurrence with noninvasive luminescence imaging. In clinical settings, blood was withdrawn from 16 breast cancer patients before and after the tumor resection, and the effect of lumpectomy on blood endocan level was evaluated. Additionally, the blood endocan from 20 patients diagnosed with postoperative recurrence was measured, and their positivity rate for endocan was compared with that for serum carcinoembryonic antigen (CEA) or cancer antigen 15-3 (CA15-3).
Our preclinical and clinical experiments revealed that blood endocan levels reflected tumor burden. Furthermore, over 60% of patients suffering from postoperative recurrence who tested negative for CEA or CA15-3 were positive for endocan.
Our results support the clinical significance of endocan in breast cancer patients for detecting breast cancer recurrence.
内消旋-精氨酸加压素（Endocan）被报道对乳腺癌患者有负面影响，并且可以从患者的血液中检测到。
本研究旨在探讨在 ESM1 高表达的乳腺癌患者中，与现有肿瘤标志物相比，测量血液内消旋-精氨酸加压素是否可以作为检测术后复发的有效工具。
从乳腺癌的小鼠模型中采集肿瘤切除前后的血液，并通过非侵入性发光成像来测量内消旋-精氨酸加压素水平，以可视化转移复发。在临床环境中，从 16 名乳腺癌患者在肿瘤切除前后抽取血液，并评估乳房肿瘤切除术对内消旋-精氨酸加压素水平的影响。此外，还测量了 20 名诊断为术后复发的患者的血液内消旋-精氨酸加压素，并将其内消旋-精氨酸加压素的阳性率与血清癌胚抗原（CEA）或癌抗原 15-3（CA15-3）进行了比较。
我们的临床前和临床实验表明，血液内消旋-精氨酸加压素水平反映了肿瘤负担。此外，超过 60%的 CEA 或 CA15-3 检测阴性的术后复发患者内消旋-精氨酸加压素检测呈阳性。
我们的结果支持内消旋-精氨酸加压素在乳腺癌患者中用于检测乳腺癌复发的临床意义。
